BioSpace News Archive

Assembly Biosciences, Inc. (Nasdaq: ASMB), a clinical-stage biotechnology company developing innovative antiviral therapeutics targeting serious viral diseases, today announced the selection of development candidate ABI-5366 (5366) to progress to IND-enabling studies for its long-acting herpes simplex virus type 2 (HSV-2) helicase inhibitor program.

ProPhase Labs, Inc., a growth oriented and diversified diagnostics, genomics and biotech company, provided a business update with respect to its wholly-owned contract manufacturing subsidiary, Pharmaloz Manufacturing, Inc..

Sotera Health Company announced its plans to release its financial results for the fourth-quarter and full-year ended December 31, 2022 before the market opens on Tuesday, February 28, 2023.

AnPac Bio-Medical Science Co., Ltd. (the “Company”) (NASDAQ: ANPC) announced the closing of the acquisition of GISN (HK) LIMITED (“GISN”), a technical solution and outsourcing consulting services provider focused on the digital, internet and Web 3 business transformation for start-ups and traditional enterprises.

Elevance Health (NYSE: ELV) today announced the closing of its acquisition of BioPlus, a comprehensive specialty pharmacy subsidiary of CarepathRx, a portfolio company of Nautic Partners.

Shanghai Junshi Biosciences Co., Ltd (“Junshi Biosciences”, HKEX: 1877; SSE: 688180) and Coherus BioSciences, Inc. (“Coherus”, Nasdaq: CHRS) today announced positive results of a final analysis of overall survival (“OS”) from the pivotal study JUPITER-02 (NCT03581786).

Cryoport, Inc. (Nasdaq: CYRX) (“Cryoport” or the “Company”) today announced that the Company will report financial results for the fourth quarter and year ended December 31, 2022 on Thursday, February 23, 2023 after U.S. markets close.

Sera Prognostics Inc., The Pregnancy Company® (NASDAQ: SERA) today announced top-line results from the AVERT PRETERM TRIAL (Serum Assessment of Preterm Birth Outcomes Compared to Historical Controls), conducted at ChristianaCare in Wilmington, Delaware.

Medigene AG (Medigene, FSE: MDG1, Prime Standard), an early-stage immuno-oncology platform company focusing on the discovery and development of T cell immunotherapies for solid tumors, will be presenting at the 6th Annual CAR-TCR Summit Europe in London from February 21 to 23, 2023.

RadioMedix, Inc. (“RadioMedix” or “Company”), a clinical-stage radiopharmaceutical company announced the acquisition of it’s 225Ac-PSMA-I&T asset by Fusion Pharmaceuticals.